Incidence of abacavir hypersensitivity reactions in EuroSIDA

Antiviral Therapy

Volumn 13, Issue 5, 2008, Pages 687-696

  Bannister, Wendy P ^a   Friis Møller, Nina ^b   Mocroft, Amanda ^a   Viard, Jean Paul ^c   van Lunzen, Jan ^d   Kirk, Ole ^b   Gargalianos, Panagiotis ^e   Bánhegyi, Dénes ^f   Chiesi, Antonio ^g   Lundgren, Jens D ^b,h  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e IASO GENERAL HOSPITAL   (Greece)

^f Szent Laszlo Hospital   (Hungary)

^g ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^h University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; COTRIMOXAZOLE; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; LAMIVUDINE; MALE; MIDDLE AGED; POISSON DISTRIBUTION; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 49949094089     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis 2002; 34:1137-1142.
2. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection. 2006 Recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-843.
3. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 29 January 2008. Accessed 8 July 2008.) Available from http://aidsinfo.nih.gov
4. Hetherington S, McGuirk S, Powell G et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603-1614.
5. Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002; 24:1502-1514.
6. Calmy A, Hirschel B, Cooper DA, Carr A. Clinical update: adverse effects of antiretroviral therapy. Lancet 2007; 370:12-14.
7. de la Rosa R, Harris M, Uyeda L, Goodison K, Keown P, Montaner JSG. Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient. AIDS 2004; 18:578-579.
8. Escaut L, Yves J, Albengres E, Cheminot N, Vittecoq D. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS 1999; 13:1419.
9. Walensky RP, Goldberg JH, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS 1999; 13:999-1000.
10. Bartlett JA, Mole LA, Fusco JS, Baker RK, Nordstrom BL. Frequency of abacavir (ABC) hypersensitivity reactions (HSR), rechallenge reactions, and HSR-attributable outcomes are similar with the use of Ziagen or Trizivir: final results from the Trizivir Epidemiology Study. 3rd IAS Conference on HIV Pathogenesis and Treatment. 24-27 July 2005, Rio De Janeiro, Brazil. Abstract TuPe2.1B01.
11. Chung W-H, Hung S, Chen Y-T. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007; 7:317-323.
12. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-1122.
13. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5:203-211.
14. Zucman D, de Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B* 5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45:1-3.
15. Mallal S, Phillips EJ, Carosi G, et al. HLA-B* 5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
16. Mallal S, Nolan D, Witt C, et al. Association between resence of HLA-B* 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
17. Rauch A, Nolan D, Martin AM, McKinnon E, Almeida C-M, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort Study. Clin Infect Dis 2006; 43:99-102.
18. Lucas A, Nolan D, Mallal S. HLA-B* 5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother 2007; 59:593.
19. Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis 2006; 43:103-105.
20. Phillips EJ, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007; 7:324-330.
21. Hughes CA, Foisy MM, Dewhurst N, et al. Abacavir hypersensitivity reaction: an update (March). Ann Pharmacother 2008; 42:387-396.
22. Cutrell A, Hernandez JE, Fleming JW, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 2004; 38:2171-2172.
23. Easterbrook PJ, Waters A, Murad S, et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med 2003; 4:321-324.
24. Stekler J, Maenza J, Stevens C, et al. Abacavir hypersensitivity reaction in primary HIV infection. AIDS 2006; 20:1269-1274.
25. Symonds W, Cutrell A, Edwards MT, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002; 24:565-573.
26. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and Tath rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
27. Bannister WP, Kirk O, Gatell JM, et al. Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr 2006; 42:229-237.
28. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-411.
29. Kiepiela P, Leslie AJ, Honeyborne I, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432:769-775.
30. Haynes BE, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996; 271:324-328.
31. Rodríguez-Nóvoa S, García-Gascó P, Blanco F, et al. Value of the HLA-B* 5701 allele to predict abacavir hypersensitivity in Spaniards. AIDS Res Hum Retroviruses 2007; 23:1374-1376.